SCHEMBL4461703

SCHEMBL4461703

CCOc1ccc(N(c2cccnc2)C(c2cccnc2)c2cccnc2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 4/20 0.43
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SLC6A2 P23975 3/20 0.37
SLC6A4 P31645 3/20 0.37
NPC1 O15118 1/20 0.36
MAPT P10636 3/20 0.36
NOTUM Q6P988 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CFTR P13569 1/20 0.34
SLC6A3 Q01959 1/20 0.34
GOPC Q9HD26 1/20 0.34
CYP19A1 P11511 2/20 0.34
GAA P10253 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4459578 0.95 KCNA5 (0.43) KCNA5LMNASMN1; SMN2L3MBTL1SLC6A2
SCHEMBL4458827 0.92 CYP19A1 (0.43) KCNA5LMNASMN1; SMN2L3MBTL1MAPT
SCHEMBL13971458 0.90 ELOVL1 (0.42) KCNA5LMNASMN1; SMN2L3MBTL1SLC6A2
SCHEMBL4460589 0.89 CYP19A1 (0.46) KCNA5SLC6A2SLC6A4MAPTCYP19A1
SCHEMBL4461911 0.87 CYP19A1 (0.46) KCNA5LMNASLC6A2SLC6A4MAPT
SCHEMBL4457212 0.86 KCNA5 (0.42) KCNA5SLC6A2SLC6A4KMT2ACFTR
SCHEMBL4459300 0.84 KCNA5 (0.36) KCNA5LMNASMN1; SMN2L3MBTL1SLC6A2
SCHEMBL4453034 0.84 KCNA5 (0.33) KCNA5LMNASMN1; SMN2L3MBTL1SLC6A2
SCHEMBL4456913 0.84 KCNA5 (0.44) KCNA5LMNASMN1; SMN2L3MBTL1SLC6A2
SCHEMBL4461835 0.83 CYP19A1 (0.40) KCNA5SLC6A2SLC6A4KMT2ACFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP claimed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO claimed
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030043-A1 Potassium Channel Inhibitors KCNJ2, KCNH2, KCNH3 KCNA5 11/4885LMNA 904/4885SMN1; SMN2 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.